Loading...
01/11 16:02
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary highlights strong revenue growth across key segments, disciplined cash flow management, and a solid cash position. Q&A insights reveal confidence in continued demand, growth from acquisitions, and strategic investments, despite some avoidance of specific details. The positive sentiment is reinforced by the company's broad-based strength, execution, and alignment with policy goals. Overall, the company's performance and outlook suggest a positive stock price movement over the next two weeks.
Total company revenue $64 billion, increased by 22% year-over-year, primarily driven by strong demand in pharma and growth across all 5 operating segments.
Gross profit $2.3 billion, grew by 22% year-over-year, outpacing SG&A growth.
SG&A expenses $1.5 billion, increased by 14% year-over-year, with more modest growth excluding acquisitions.
Operating earnings Grew by 37% year-over-year, driven by strong performance across all segments.
EPS (Earnings Per Share) $2.55, increased by 36% year-over-year, supported by share repurchases and strong operational performance.
Pharmaceutical and Specialty Solutions revenue $59 billion, increased by 23% year-over-year, driven by Brand and Specialty Pharmaceutical sales growth and approximately 6 percentage points of growth from GLP-1 sales.
Pharma segment profit $667 million, increased by 26% year-over-year, driven by Brand and Specialty Products, MSO platforms, and positive generic program performance.
GMPD revenue $3.2 billion, increased by 2% year-over-year, driven by volume growth from existing customers.
GMPD segment profit $46 million, increased by $38 million year-over-year, driven by growth from existing customers and cost control measures.
Other segment revenue $1.6 billion, increased by 38% year-over-year, reflecting strong demand across all 3 businesses.
Other segment profit $166 million, increased by 60% year-over-year, driven by strong growth across all 3 businesses, including the acquisition of ADS.
Theranostics revenue growth Over 30% year-over-year, driven by strong demand in Nuclear and Precision Health Solutions.
OptiFreight revenue growth Over 20% year-over-year, driven by volume uplift and investments in proprietary technology.
Adjusted free cash flow $1.3 billion, generated during the first quarter, reflecting disciplined cash flow management.
Cash position $4.6 billion at the end of the quarter, including $1 billion raised for the Solaris Health transaction.
New Consumer Health Logistics Center: Opened a state-of-the-art facility to enhance supply chain efficiency, adding 20% network capacity.
New Forward Distribution Center: Announced plans for a 230,000 sq. ft. flagship center in Indianapolis with advanced automation.
Theranostics Expansion: Investing $150 million over 3 years to expand PET network and theranostics capabilities.
Solaris Health Acquisition: Acquiring the largest urology MSO in the U.S., expanding reach to 3,000 specialty providers across 32 states.
BioPharma Solutions Growth: Achieved over 30% growth in fiscal '26, driven by new business wins and next-gen hub implementation.
Cost Management: SG&A growth controlled at 14%, with focus on efficiency initiatives and cost control.
ADS Integration: Progressing well with synergies realized earlier than planned, enhancing at-Home Solutions.
Specialty Alliance Expansion: Enhancing multi-specialty MSO platform with Solaris Health, focusing on autoimmune, urology, and oncology.
Investment in Automation: Modernizing distribution centers with robotics and automation to improve efficiency and service levels.
Tariffs: The company faces a net headwind from tariffs, with a step-up in tariff costs expected in the second quarter. This could impact profitability, particularly in the GMPD segment.
Financing Costs: Interest and other expenses increased due to financing costs related to acquisitions, including Solaris Health. This adds financial pressure despite the anticipated benefits of the acquisitions.
Supply Chain Resilience: While the company has been recognized for supply chain resilience, maintaining this level of performance amidst increasing demand and expansion efforts could pose challenges.
Regulatory and Legislative Environment: The company is monitoring a dynamic legislative and regulatory environment, which could introduce uncertainties or compliance costs.
Integration of Acquisitions: The integration of recent acquisitions like Solaris Health and ADS requires significant effort and resources. Any delays or inefficiencies could impact expected synergies and financial performance.
Tariff Mitigation: Efforts to mitigate tariff impacts for customers and maintain financial commitments could strain resources and operational focus.
Operational Efficiency: Investments in automation and modernization of distribution centers are critical but could face delays or cost overruns, impacting operational efficiency.
Economic Uncertainty: Broader economic uncertainties could affect demand for the company's products and services, particularly in discretionary areas like home health care.
EPS Guidance: Raised full year EPS guidance to a range of $9.65 to $9.85, reflecting 17% to 20% growth from the prior year.
Adjusted Free Cash Flow: Increased guidance to a new range of $3 billion to $3.5 billion for the full year.
Pharma Revenue Growth: Increased guidance to 15% to 17% growth from the previous 11% to 13% growth, driven by positive demand trends.
Pharma Segment Profit Growth: New guidance range of 16% to 19% growth, up from the prior range of 11% to 13% growth, including approximately 3 percentage points of growth from Solaris Health.
GMPD Revenue and Profit: Continued expectation of 2% to 4% revenue growth and at least $140 million in segment profit, despite anticipated tariff costs.
Other Growth Businesses: Revenue guidance remains at 26% to 28% growth, with segment profit guidance increased to 29% to 31%, driven by strong performance across all three growth businesses.
Capital Expenditures: Increased expectations for CapEx to a range of $600 million to $650 million for planned investments into the Specialty Alliance platform.
Diluted Weighted Average Shares: Lowered outlook to approximately 238 million shares, reflecting Q1 and anticipated baseline share repurchases.
Dividends Paid: $125 million in dividends were paid to shareholders during the first quarter of fiscal year 2026.
Share Repurchase Program: A $375 million accelerated share repurchase program was launched in the first quarter of fiscal year 2026. This is part of a $750 million baseline share repurchase plan for the fiscal year.
The earnings call summary highlights strong revenue growth across key segments, disciplined cash flow management, and a solid cash position. Q&A insights reveal confidence in continued demand, growth from acquisitions, and strategic investments, despite some avoidance of specific details. The positive sentiment is reinforced by the company's broad-based strength, execution, and alignment with policy goals. Overall, the company's performance and outlook suggest a positive stock price movement over the next two weeks.
The earnings call summary presents a mixed outlook. Basic financial performance and expenses show stability, but the lack of clear guidance and reliance on future updates creates uncertainty. Product development and market strategy have potential with AI initiatives, yet the absence of immediate implementation limits positivity. Shareholder return plans are not explicitly outlined, and while Wholesale Banking growth is positive, flat deposit growth and unclear management responses temper enthusiasm. Overall, the sentiment is neutral due to balanced positives and negatives, with no strong catalysts for significant stock movement.
The earnings call reveals mixed signals: EPS missed expectations, but there is a positive outlook for mortgage demand and a strong share buyback program. Operating expenses increased, and there are macroeconomic uncertainties and geopolitical risks. The Q&A section showed management's cautious approach, with some ambiguity in guidance. These factors balance out, leading to a neutral sentiment with potential short-term volatility.
The earnings call presents a mixed picture. Positives include a strong shareholder return plan with a significant share buyback, robust fee income growth, and a solid CET1 ratio. However, risks from geopolitical uncertainties, macroeconomic conditions, and potential impacts on margins from interest rate volatility balance these positives. The Q&A section reveals some management evasiveness, particularly concerning lending margin guidance, which could raise concerns. Overall, the blend of positive shareholder returns and cautious financial outlook results in a neutral sentiment, likely leading to a stock price movement within -2% to 2%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
